LDN Dosage Guide: Complete Titration Protocol & Best Practices

Proper dosing is essential for achieving therapeutic benefit with Low Dose Naltrexone while minimizing side effects. This guide provides our evidence-based titration protocol used by Salutaris RX physicians, adapted from published clinical protocols and refined through clinical experience with thousands of patients.

Phase 1 - Initiation (Days 1-14): Dose: 1.5mg at bedtime Purpose: Allows the body to adjust to the transient opioid receptor blockade. Most initial side effects (vivid dreams, mild headache) present during this phase and often resolve spontaneously. Phase 2 - Intermediate (Days 15-28): Dose: 3.0mg at bedtime Purpose: Intermediate dose that provides meaningful immune modulation while continuing the adjustment process. Many patients with fibromyalgia and chronic fatigue report initial symptom improvement at this dose. Phase 3 - Therapeutic (Day 29+): Dose: 4.5mg at bedtime Purpose: Standard therapeutic dose used in the majority of clinical trials. This is the target dose for most patients, though some achieve optimal benefit at 3.0mg.

Bedtime dosing (9-11 PM) is strongly recommended for several reasons: - The transient opioid blockade coincides with the natural nocturnal endorphin surge (approximately 2-4 AM), maximizing the rebound upregulation effect - Sleep-related side effects (vivid dreams) are less disruptive when they occur during natural sleep cycles - Steady-state endorphin elevation is maintained throughout the following day Some patients, particularly those experiencing persistent sleep disruption, may benefit from morning dosing. This should be discussed with your prescribing physician.

Vivid Dreams (Most Common): Experienced by approximately 37% of patients during the first 2 weeks. Strategy: Ensure adequate sleep hygiene, consider temporary dose reduction to 1.0mg, or shift dosing 1-2 hours earlier. Headache: Typically mild and transient, occurring in approximately 15% of patients. Strategy: Over-the-counter acetaminophen is appropriate. Do not use NSAIDs regularly as they may interfere with the immune-modulatory mechanism. Nausea: Rare (<5% incidence), usually mild. Strategy: Take with a small snack. If persistent, reduce dose and titrate more slowly. Insomnia: Uncommon but can occur. Strategy: Trial morning dosing. If persistent beyond 2 weeks at any dose, reassess with your physician.

Thyroid Patients (Hashimoto's): LDN may enhance immune function sufficiently to reduce thyroid antibodies. Monitor TSH every 4-6 weeks initially, as thyroid medication dosage may need adjustment. Pediatric Use: Limited evidence exists for pediatric use. When prescribed off-label, doses are typically weight-based (0.1mg/kg) with slower titration. Elderly (>65): Consider starting at 1.0mg with a 3-week titration per dose increase. Renal clearance may be reduced, resulting in longer duration of action. Pregnancy/Breastfeeding: Insufficient safety data. LDN should be discontinued at least 30 days before planned conception.